BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9538169)

  • 21. Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy.
    Izycki T; Chyczewska E; Naumnik W; Talalaj J; Panek B; Ossolinska M
    Exp Oncol; 2004 Dec; 26(4):316-9. PubMed ID: 15627066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
    Imaizumi M;
    Lung Cancer; 2005 Jul; 49(1):85-94. PubMed ID: 15949594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between tumor necrosis factor-alpha and D-dimer levels in non-small cell lung cancer patients.
    Guadagni F; Ferroni P; Basili S; Facciolo F; Carlini S; Crecco M; Martini F; Spila A; D'Alessandro R; Aloe S; Cerasoli V; Del Monte G; Mariotti S; Mineo TC; Roselli M
    Lung Cancer; 2004 Jun; 44(3):303-10. PubMed ID: 15140543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer.
    Han JY; Choi BG; Choi JY; Lee SY; Ju SY
    Lung Cancer; 2006 Nov; 54(2):227-34. PubMed ID: 16935391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum levels of angiopoietin-1, angiopoietin-2, and their receptor tie-2 in patients with nonsmall cell lung cancer during chemotherapy.
    Naumnik W; Chyczewska E; Ossolinska M
    Cancer Invest; 2009 Aug; 27(7):741-6. PubMed ID: 19340656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer.
    Jin B; Huang AM; Zhong RB; Han BH
    Chemotherapy; 2010; 56(6):417-23. PubMed ID: 21079400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer.
    Ujiie H; Tomida M; Akiyama H; Nakajima Y; Okada D; Yoshino N; Takiguchi Y; Tanzawa H
    Anticancer Res; 2012 Aug; 32(8):3251-8. PubMed ID: 22843899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of plasma TGF-β1 level in predicting therapeutic efficacy and prognosis in patients with advanced non-small cell lung cancer.
    Kumar S; Guleria R; Mohan A; Singh V; Bharti AC; Das BC
    Cancer Invest; 2011 Mar; 29(3):202-7. PubMed ID: 21280981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C-reactive protein as a monitor of chemotherapy response in advanced non-small cell lung cancer (CML study).
    Srimuninnimit V; Ariyapanya S; Nimmannit A; Wonglaksanapimon S; Akewanlop C; Soparattanapaisarn N
    J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S199-207. PubMed ID: 22574550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer.
    Qian Q; Zhan P; Yu L; Shi Y; Cheng J; Wei S; Wang Q; Song Y
    Clin Lung Cancer; 2011 Mar; 12(2):131-7. PubMed ID: 21550560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma.
    Oka M; Yamamoto K; Takahashi M; Hakozaki M; Abe T; Iizuka N; Hazama S; Hirazawa K; Hayashi H; Tangoku A; Hirose K; Ishihara T; Suzuki T
    Cancer Res; 1996 Jun; 56(12):2776-80. PubMed ID: 8665513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer.
    Tas F; Duranyildiz D; Argon A; Oğuz H; Camlica H; Yasasever V; Topuz E
    Med Oncol; 2005; 22(4):353-8. PubMed ID: 16260852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy.
    Chang CH; Hsiao CF; Yeh YM; Chang GC; Tsai YH; Chen YM; Huang MS; Chen HL; Li YJ; Yang PC; Chen CJ; Hsiung CA; Su WC
    Int J Cancer; 2013 May; 132(9):1977-85. PubMed ID: 23034889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival.
    Orditura M; Romano C; De Vita F; Galizia G; Lieto E; Infusino S; De Cataldis G; Catalano G
    Cancer Immunol Immunother; 2000 Dec; 49(10):530-6. PubMed ID: 11129323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer.
    Shang GH; Jia CQ; Tian H; Xiao W; Li Y; Wang AH; Dong L; Lin DJ
    Respir Med; 2009 Dec; 103(12):1949-53. PubMed ID: 19535236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum cytokines and tumour markers in patients with non-small cell carcinoma of the lung.
    Bansal AS; Bruce J; Devine PL; Scells B; Zimmermann PV
    Dis Markers; 1997 Nov; 13(3):195-9. PubMed ID: 9405932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Dry extract of Scutellaria baicalensis as a hemostimulant in antineoplastic chemotherapy in patents with lung cancer].
    Gol'dberg VE; Ryzhakov VM; Matiash MG; Stepovaia EA; Boldyshev DA; Litvinenko VI; Dygaĭ AM
    Eksp Klin Farmakol; 1997; 60(6):28-30. PubMed ID: 9460593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum interleukin-17 as a diagnostic and prognostic marker for non-small cell lung cancer.
    Xu C; Hao K; Yu L; Zhang X
    Biomarkers; 2014 Jun; 19(4):287-90. PubMed ID: 24731052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.